Infectious Disease Drug Market
Infectious diseases are those which are usually caused by microorganisms such as viruses, bacteria, parasites, and fungi which usually live in or on our body. These diseases can be caused from person to person, insects, or animals. Persons who have probably developed a weakened immune system may have been susceptible to infection. Usually the symptoms of this condition depend upon the organism which causes the infection. Due to climate change, the prevalence of infectious diseases has increased. Some of the common infectious diseases are Lyme disease, jaundice, listeria, ebola, severe acute respiratory syndrome, west nile, among others. Today, there are various drugs available in the market so they can be cured easily. Few of the common drugs which are used are omadacycline, tecovirimat, tafenoquine, benzidazole, daclatasvir, among others.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-infectious-disease-drug-market
Some of the launches and acquisitions in the Infectious Disease Drug Market are as follow:
The global infectious disease drug market is segmented on the basis of source type as bacterial diseases, virusal diseases, fungal disease and parasitic disease; disease type as jaundice, leprosy, listeria, lyme disease, malaria, measles, molluscum contagiosum, molluscum contagiosum, norovirus, pyelonephritis, rabies, severe acute respiratory syndrome, sepsis, tetanus, west nile, zika, ebola disease and others; treatment type as medication, dietary supplements and surgery; mode of action type as antibacterial drugs, antiviral drugs, antifungal drugs, antiparasitic drugs; drug type (tafenoquine, omadacycline, tecovirimat, eravacycline, delafloxacin, plazomicin, benznidazole, secnidazole, daclatasvir, dalbavancin and others; route of administration as oral, topical and intravenous and end- users as hospitals, homecare, specialty clinics, others.
“According to Data Bridge Market Research, Global Infectious Disease Drug Market is set to witness substantial 5.5% in the forecast period of 2019- 2026”
Few of the major competitors currently working in the Infectious Disease market are F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), GlaxoSmithKline Plc (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc. (US), AbbVie Inc. (US), Vertex Pharmaceuticals Incorporated (US), ViiV Healthcare group of companies (UK), Sanofi S.A (France), Eli Lilly and Company (US) , Novartis AG (Switzerland), Mitsubishi Tanabe Pharma Corporation (Japan) and few among others.
Growing prevalence for infectious diseases and increasing demand for personalized medicines are the factor for the market growth. Government is also taking many initiatives and investing for the infectious disease diagnostics. Technological advancement and development in genomics and proteomics is another factor affecting the market positively. These are some of the factors which are creating new opportunities for this market.
Browse in Healthcare Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/